Astellas Licenses Antibody Technology From Kyowa Hakko Kirin
This article was originally published in PharmAsia News
Kyowa Hakko Kirin U.S. subsidiary Biowa announced a licensing agreement with Astellas subsidiary Agensys. Biowa will provide proprietary Potelligent antibody technology to Agensys in exchange for a licensing fee. California-based Agensys is a biopharmaceutical venture firm focusing on antibody cancer drug development. The company was acquired by Astellas in 2007. (Click here for more - Japanese language
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.